The protective effects of Fufang Biejiafang on bleomycin-induced pulmonary fibrosis in rats.
- Author:
Lu KONG
1
;
Ji-feng WANG
;
Jian-zhao NIU
;
Zhi-gang XIA
;
Chen QIAO
;
Yan-fei WEI
;
Heng-jing TU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Bleomycin; Blood Gas Analysis; Bronchoalveolar Lavage Fluid; cytology; Drugs, Chinese Herbal; isolation & purification; pharmacology; Male; Materia Medica; isolation & purification; pharmacology; Paeonia; chemistry; Panax; chemistry; Plants, Medicinal; chemistry; Protective Agents; pharmacology; Pulmonary Fibrosis; chemically induced; metabolism; pathology; Pulmonary Surfactants; metabolism; Random Allocation; Rats; Rats, Sprague-Dawley; Turtles
- From: China Journal of Chinese Materia Medica 2005;30(3):204-207
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the possible effects and mechanism of Fufang Biejiafang on a single intratracheal instillation (IT) of bleomycin-induced lung fibrosis model.
METHODSD rats were treated with a single IT dose of bleomycin or control saline. Chinese medicine group were poured into the stomach after the first day of operation with high dosage, middle dosage and low dosage. On days 7, 14 and 28 following IT bleomycin or saline, 4 mL blood were taken from the abdominal aorta for arterial blood gas analysis. The left lung was fixed for routine light microscopic examination. Bronchoalveolar lavage fluid (BALF) from the right lung was tested the activity of pulmonary surfactant (PS) by the Whihelmy Film Balance, then the right lung was frozen immediately in liquid nitrogen for determination of hydroxyproline concentration.
RESULTModel rats had obviously changes of body weight and hypoxemia and dysfunction of PS on days 7 and improved on days 14. Compared with three dose groups, the middle dose group some degreely improved and PS function. It ameliorate fibrosis because of inhibition of inflammation.
CONCLUSION(1) PS dysfunction resulted in hypoxemia after bleomycin injured alveolar type II (AT II). Fufang biejiafang-middle dose-group ameliorate hypoxemia by remission AT-II injury. (2) Fufang biejiafang may inhibit exudation inflammation and ameliorate fibrosis.